We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
KEYTRUDA Merck Sharp & Dohme (Australia) Pty Ltd
Product name
KEYTRUDA
Accepted date
Apr-2026
Active ingredients
pembrolizumab
Summary of proposed indication
KEYTRUDA (pembrolizumab), in combination with sacituzumab govitecan, is indicated for the treatment of patients with unresectable locally advanced or metastatic TNBC whose tumours express PD-L1 (CPS ≥10) as determined by a validated test.
Application type
C (new indication)
Publication date
Apr-2026